Global Breast Cancer Monoclonal Antibodies Market

Cancer biologics refer to a substance used in the prevention, detection, or treatment of cancer and other disorders that is created from a living creature or its byproducts. Immunoglobulins, interleukins, and vaccinations are examples of biologic agents. A form of cancer treatment known as "biological therapy" employs the body's immune system to eradicate cancer cells. The main types of cancer biologics are monoclonal antibodies, vaccines, cell and gene therapy, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. It is used in non-small cell lung cancer, prostate cancer, breast cancer, acute myeloid leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, gastric cancer, and others, and is distributed through various channels such as hospitals, clinics, and others. The cancer biologics market research report is one of a series of new reports from The Business Research Company that provides cancer biologics market statistics, including cancer biologics industry global market size, regional shares, competitors with a cancer biologics market share, detailed cancer biologics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biologics industry. This cancer biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cancer biologics market grew from $86.64 billion in 2022 to $96.33 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The cancer biologics market is expected to grow from $140.88 billion in 2027 at a CAGR of 10.0%. The rising prevalence of chronic diseases is one of the major factors driving the cancer biologics market's growth. Chronic disorders are diseases that persist over a long period and hinder the health of people with disabilities, and cancer is one of the most common chronic diseases. The most common cancers are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. According to the World Health Organization (WHO), in 2020, chronic diseases accounted for 75% of deaths globally. Therefore, the rising prevalence of chronic diseases is expected to drive the growth of the cancer biologics market over the coming years. The cancer biologics market is being restrained by the adverse effects associated with the use of cancer biologics. Biologic drugs are administered by injection or infusion, as they are proteins that are quickly digested and inactivated if given by mouth, so they can cause injection site reactions or infusion reactions. Moreover, the adverse effects of the biologics vary from common side effects such as allergic reactions and diarrhoea to serious adverse effects such as low blood pressure, hepatitis, and hypothyroidism. For instance, according to a study conducted by NCBI, biological agents are essential additions to chemotherapy for GI malignancies that leads to enhanced survival response rates, but these additions also bring some unique adverse reactions to the patients. Companies in the cancer biologics market are developing predictive biomarkers that help physicians decide the treatments for their patients by utilising physiological biomarkers for predicting performance. Predictive biomarkers study tumour growth in patients by analysing the major etiological factors, as the cancer etiology differs from patient to patient. Moreover, these biomarkers not only aid in the early detection of cancer but also help in deciding the most cost-effective treatment regimens, especially for the biologics based on gene therapy. According to the FDA approval process for new cancer treatments and biological products, the application for approval should include all relevant data available from clinical studies, including negative results as well as positive findings. Data can come from pharmaceutical company-sponsored clinical trials intended to test the safety and effectiveness of a new use of a product, or from several alternative sources. In May 2020, Boehringer Ingelheim, a Germany-based, research-driven pharmaceutical company, acquired Northern Biologics for an undisclosed amount. This acquisition would provide Boehringer Ingelheim with two additional assets to add to its existing cancer immunology portfolio that complement Northern Biologics' current offerings, supporting the company's goal to target "cold" tumours with synergistic combination methods. The acquisition includes Northern Biologics’ preclinical cancer antibody pipeline, which is expanding its immuno-oncology portfolio. Northern Biologics is a Canada-based clinical-stage biotechnology company. Major players in the cancer biologics market are AbbVie Inc., Hoffman-La Roche, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co., Inc., Novartis, and Pfizer. North America was the largest region in the cancer biologics market in 2022. The Middle East is expected to be the fastest growing region in the global cancer biologics market during the forecast period. The regions covered in the global cancer biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The cancer biologics market consists of sales of cancer vaccines, cytokine therapy, and angiogenesis inhibitors. Values in this market are factory gate values which are the values of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global cancer biologics market is segmented - 1) By Type: Monoclonal Antibodies, Vaccines, Cell and Gene Therapy, Other Types 2) By Application: Non-small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Ovarian Cancer, Colorectal Cancer, Gastric Cancers, Other Applications 3) By Distribution Channel: Hospitals, Clinics, Other Distribution Channels

Breast cancer drugs refer to anti-cancer medications that can be taken orally or intravenously (injected into a vein). The majority of the body's cancer cells are reached by the medications via the bloodstream. Chemotherapy may occasionally be administered directly into this region if cancer has spread to the spinal fluid, which surrounds and protects the brain and spinal cord (called intrathecal chemotherapy). The main drug types in breast cancer drugs are HER2 inhibitors, mitotic inhibitors, anti-metabolites, aromatase inhibitors, and hormonal receptors. A mitotic inhibitor is a medication that prevents cell division, or mitosis. These medications disrupt microtubules, which pull the chromosomes apart as a cell dividesetabolites, aromatase inhibitors, and hormonal receptors. A mitotic inhibitor is a medication that prevents cell division, or mitosis. These medications disrupt microtubules, which pull the chromosomes apart as a cell divides. The different types include metastatic breast cancer, triple-negative breast cancer, and others (ductal carcinoma in situ, invasive ductal carcinoma, inflammatory breast cancer, breast cancer during pregnancy, and others). The several sectors include hospitals, clinics, and others and are distributed through various channels, such as ambulatory surgical centers, hospitals, clinics, retail pharmacies, and online channels. The breast cancer drugs market research report is one of a series of new reports from The Business Research Company that provides breast cancer drugs market statistics, including breast cancer drugs industry global market size, regional shares, competitors with a breast cancer drugs market share, detailed breast cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer drugs industry. This breast cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global breast cancer drugs market size will grow from $31.50 billion in 2022 to $33.96 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global breast cancer drugs market size is expected to grow to $44.11 billion in 2027 at a CAGR of 6.8%. The increasing prevalence of breast cancer is driving the breast cancer drug market. Breast cancer is the most common type of cancer among women and affects around 2.1 million women each year. According to the World Health Organization, breast cancer affected 2.3 million women globally in 2020, with 685 000 fatalities. The factors responsible for breast cancer include the heredity, age, and lifestyle of a person, and are more common in developed countries. As the number of people diagnosed with breast cancer rises, the demand for breast cancer drugs increases, thereby driving the market growth. Adverse side effects caused by the use of breast cancer drugs are acting as a restraint on the breast cancer drugs market. Breast cancer drugs can result in long-term or short-term side effects including headaches, dental issues, osteoporosis, heart problems, cataracts, blood clots, infertility, and others. As a result, patients depend on alternate or complementary treatments to deal with the side effects, thereby increasing overall treatment costs. Also, the long-lasting nature of some of the side effects discourages the use of breast cancer drugs, affecting the market growth. Manufacturers of breast cancer drugs are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For instance, AstraZeneca entered into a partnership deal worth $6.9 billion for the development of a breast cancer drug. According to the deal, the companies will jointly develop the drug trastuzumab deruxtecan and will share development and commercialization costs for the drug worldwide. Novartis collaborated with IBM Watson Health for the development of a solution that can determine drug combinations and sequences for the best patient outcomes. Manufacturers of breast cancer drugs are governed by various regulatory bodies, such as the Food and Drug Administration in the USA and the European Medicines Agency in the European Union. The European Medicines Agency (EMA) regulates the market for breast cancer drugs by granting licences to the drugs that have been proven to be safe and clinically effective. The drug is evaluated to understand its benefits and risks and then tested for any post-usage effects. The drug can be commercially sold in the European Union upon approval from the EMA. The EMA can also grant a conditional marketing authorization indicating approval but can withdraw it if found unsafe or ineffective. Major players in the breast cancer drugs market are F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca, Eli Lilly and Company, Celgene Corporation, Biocon, Merck & Co. Inc., Genzyme Corporation, Janssen Global Services LLC, and MacroGenics Inc. North America was the largest region in the breast cancer drugs market in 2022. The Middle East is expected to be the fastest-growing region in the global breast cancer drugs market during the forecast period. The regions covered in the global breast cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the breast cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The breast cancer drugs market consists of sales of Abemaciclib, Alpelisib, Anastrozole, and Aredia. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global breast cancer drugs market is segmented - 1) By Type: Metastatic Breast Cancer, Triple Negative Breast Cancer, Others (Ductal Carcinoma Insitu, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, Breast Cancer During Pregnancy, Others) 2) By Drug Type: HER2 Inhibitors, Mitotic Inhibitors, Anti-Metabolites, Aromatase Inhibitors, Hormonal Receptor 3) By End User: Ambulatory, Hospitals, Clinics, Other End-Users 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels

Antibody-drug conjugates (ADCs) refer to medications that are specifically designed to administer chemotherapy to cancer cells. ADCs deliver chemotherapy via a linker connected to a monoclonal antibody that binds to a specific target expressed on cancer cells.As soon as the ADC binds to its target (a cancer protein or receptor), a cytotoxic chemical is released into the cancer cell. The main types of antibody-drug conjugates are monoclonal antibodies, linkers, drugs or toxins, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different products include Adcertis, Kadcyla, and others and involve various technologies such as immunogen technology, Seattle genetics technology, immunomedics technology, and others. It is used in blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumours, and others, and is implemented in hospitals, clinics, and others. The antibody-drug conjugates (ADCs) market research report is one of a series of new reports from The Business Research Company that provides antibody-drug conjugates (ADCs) market statistics, including antibody-drug conjugates (ADCs) industry global market size, regional shares, competitors with an antibody-drug conjugates (ADCs) market share, detailed antibody-drug conjugates (ADCs) market segments, market trends and opportunities, and any further data you may need to thrive in the antibody-drug conjugates (ADCs) industry. This antibody-drug conjugates (ADCs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.. The global antibody drug conjugates market grew from $5.9 billion in 2022 to $7.2 billion in 2023 at a compound annual growth rate (CAGR) of 22.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antibody drug conjugates market is expected to grow from $16.15 billion in 2027 at a CAGR of 22.4%. The antibody-drug conjugates market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rising incidences of cancer are expected to increase the demand for antibody-drug conjugates, driving the market's growth. The challenges involved in the manufacturing of ADCs is acting as a restraint on the antibody drug conjugates market. ADC manufacturing facilities necessitate a significant capital investment as well as extensive specialised training for operators. ADC process development is complicated as it requires optimization of additional process steps that are not present in conventional monoclonal antibody manufacturing, such as the antibody-drug conjugation reaction and subsequent drug substance purification. Also, antibody-drug conjugates must be manufactured in aseptic environments, and operating personnel should be protected from the highly toxic drug compounds, thereby presenting operational difficulties. Manufacturers of antibody-drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For instance, in March 2022, Sanofi, a France-based multinational pharmaceutical and healthcare company, collaborated with a US-based biotechnology company, Seagen Inc., to create up to three cancer targets for antibody-drug conjugates (ADCs), develop them, and market them. The collaboration would make use of the exclusive monoclonal antibody (mAb) technology from Sanofi and the exclusive ADC technology from Seagen. Through this cooperation, candidate medications with the potential to give cancer patients and their families fresh hope would be created via the synergistic combination of molecules and platforms. Manufacturers of antibody-drug conjugates are monitored by various regulatory bodies, such as the Food and Drug Administration in the USA. In the USA, there is no specific regulatory guidance for the industry on ADC development, and the FDA follows existing guidelines for small drugs and monoclonal antibodies to regulate ADC. The product quality offices at the FDA, such as the Office of Biotechnology Products (OBP) and Office of Pharmaceutical Quality, primarily focus on the manufacturing of the antibody component of the ADC and the control strategy for the antibody intermediate, as well as for the drug substance (DS) and drug product (DP). The small molecule review groups in the Office of Pharmaceutical Quality bear primary responsibility for the review of the adequacy of the payload and linker, conjugation reactions, and aspects of the control strategy. Major players in the antibody-drug conjugates (ADCs) market are Bayer AG, Concortis Biotherapeutics, F. Hoffmann-La Roche Ltd., Immunomedics Inc., Oxford BioTherapeutics, Pfizer Inc., Seattle Genetics Inc., Takeda Pharmaceutical Company Limited, Abbvie Inc., and Astellas Pharma/Agensys. North America was the largest region in the antibody-drug conjugates (ADCs) market in 2022. The Middle East is expected to be the fastest growing region in the global antibody drug conjugates market during the forecast period. The regions covered in the global antibody-drug conjugates (ADCs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antibody-drug conjugates (ADCs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The antibody-drug conjugates (ADCs) market consists of sales of enfortumab vedotin, sacituzumab govitecan, trastuzumab emtansine, and trastuzumab deruxtecan. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global antibody drug conjugates market is segmented - 1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types 2) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications 3) By Product: Adcertis, Kadcyla, Other Products 4) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology 5) By End User: Hospital, Clinics, Other End Users

Radiotherapy devices are used in cancer treatment by using high doses of radiation to kill cancer cells and shrink tumors. The main product type of radiotherapy devices is external beam radiation therapy devices, linear accelerator devices, and proton therapy devices. A medical linear accelerator (LINAC) is a radiotherapy device that is generally utilized for external beam radiation treatments for patients with cancer. It supplies high-energy x-rays or electrons to the region of the patient's tumor. The applications are skin cancer, breast cancer, prostate cancer, cervical cancer, lung cancer, and others. These are used in hospitals, ambulatory surgical centers, and oncological treatment centers. The radiotherapy devices market research report is one of a series of new reports from The Business Research Company that provides radiotherapy devices market statistics, including radiotherapy devices industry global market size, regional shares, competitors with a radiotherapy devices market share, detailed radiotherapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the radiotherapy devices industry. This radiotherapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global radiotherapy devices market grew from $5.21 billion in 2022 to $5.69 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The radiotherapy devices market is expected to grow from $8.07 billion in 2027 at a CAGR of 9.1%. Technological advancement is anticipated to drive the demand for the radiotherapy devices market. The advancement in technology is helping to develop low-cost, more effective and efficient, and user-friendly products with precise and improved radiation doses for increased performance in targeting tumors. The advancement from 2D radiotherapy devices to 3D with real-time imaging enabled high conformity of radiation to improve tumor control. For instance, in June 2020, Accuray Incorporated, a US-based radiation oncology company launched CyberKnife S7 System, a radiotherapy device combining advanced precision, real-time artificial intelligence, and speed motion tracking and synchronization treatment delivery for stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatments. Therefore, the launch of advanced devices is likely to propel the revenues for the radiotherapy devices market shortly. The high cost of radiotherapy is projected to limit the growth of the radiotherapy devices market as it uses complex machines and involves the services of skilled health care providers. The specific expense of radiation treatment relies upon the expense of medicinal services such as place of patient residence, type of radiation treatment, and the number of medicines required. For example, Proton Therapy is a high-cost therapy that is usually performed in metropolitical cities or at major academic centers. The treatment duration is eight weeks, which leads to huge expenditure on treatment and relocation. According to the report of the National Cancer Institutes, approximately $150.8 billion were spent nationally for cancer care in 2018 in America. The high costs of cancer treatment are especially difficult to overcome among the poor or the uninsured or underinsured population. Therefore, the high cost associated with radiotherapy procedures is expected to restrain the growth of the market. Artificial Intelligence (AI) is a leading trend in the radiotherapy devices market and is gaining significant popularity in the market. The incorporation of AI innovation in disease care is expected to improve the exactness and speed of analysis, help clinical dynamics, and lead to better results. For instance, in October 2022, HCG cancer hospital launched AI-based radiation treatment technology for efficient radiotherapy. The traditional treatment arranging process takes days to make an improved radiation treatment conveyance plan; however, the new AI advancements are helping to speed up this procedure. AI is also expected to include deep learning applications in treatment planning, clinical decision support, automated image-guided adaptive radiation therapy, and genomic/radio-biologic data mining, thus supporting the growth of the market. In August 2020, Siemens Healthineers, a Germany-based medical technology company, announced its decision to acquire Varian Medical Systems Inc., for $16.4 billion. The deal is expected to expand Siemens Healthineer's definitive objective of overarching and comprehensive oncology portfolio, including Varian's linear accelerators, radiosurgery devices, and proton therapy suites to Siemens' imaging hardware, laboratory diagnostics, and hospital consulting services. Varian Medical Systems Inc. is a US-based radiation oncology treatments and software company. Major players in the radiotherapy devices market are Varian Medical Systems, Elekta AB, Accuray Inc., C.R.Bard Inc., IBA Ion Beam Applications SA, Koninklijke Philips N.V, Siemens AG, Eckert & Ziegler Bebig, IsoRay Inc., and GE Healthcare. North America was the largest region in the radiotherapy devices market in 2022. Asia-Pacific was the second largest region in the global radiotherapy devices market report. The regions covered in the global radiotherapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the radiotherapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The radiotherapy devices market consists of sales of external beam radiation therapy devices, linear accelerator devices, and proton therapy devices that are used for radiotherapy. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global radiotherapy devices market is segmented - 1) By Product Type: External Beam Radiation Therapy Devices, Linear Accelerator Devices, Proton Therapy Devices 2) By Application: Skin Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Lung Cancer, Other Applications 3) By End Users: Hospitals, Ambulatory Surgical Centers, Oncological Treatment Centers

Cancer diagnostic devices are used to diagnose the stage and cause of the condition by identifying the oncogenic proteins, and certain enzymes released by the tumor cells in patients. The main products in cancer diagnostics are companion diagnostics and molecular diagnostics. Molecular diagnostics is a laboratory method that is used to check for certain proteins, genes, or other molecules that may be a sign of cancer. The methods used in cancer diagnostics are biopsy, endoscopy, tumor biomarker tests, and imaging. The applications covered in cancer diagnostics are cervical cancer, breast cancer, liver cancer, blood cancer, kidney cancer, colorectal cancer, pancreatic cancer, ovarian cancer, melanoma, and others that are used by end-users such as cancer research institutes, diagnostic laboratories, hospitals, and others. The cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides cancer diagnostics market statistics, including cancer diagnostics industry global market size, regional shares, competitors with a cancer diagnostics market share, detailed cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer diagnostics industry. This cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global cancer diagnostics market size will grow from $19.18 billion in 2022 to $21.38 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global cancer diagnostics market size is expected to grow to $33.13 billion in 2027 at a CAGR of 11.6%. A high prevalence rate of various types of cancers is a major driver of the cancer diagnostics market. This is because the increasing incidences of various types of cancers are leading to a greater number of people opting for diagnosis and treatment. In addition, according to the World Health Organization (WHO), cancer was the second-leading cause of death worldwide. The National Cancer Institute (NCI) has estimated the number of new cancer cases per year to reach 23.6 million by 2030. Product recall is one of the major restraints for the cancer diagnostics market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, it takes up the cost of fixing the defective product and replacing it. This cost of replacement of cancer diagnostics devices can be very high for manufacturers, which ultimately restricts the growth of the market. For example, Siemens Healthcare Diagnostics had to recall its IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay as it was not meeting the required high-dose hook effect expectation. An IMMULITE/IMMULITE 1000 Systems Prostate-Specific Antigen (PSA) Assay can be used as an aid in the detection of prostate cancer along with digital rectal examination (DRE) in men aged 50 years or older. The AI-based cancer detection system is an emerging trend in the cancer diagnostics market. AI helps in improving the accuracy of image detection in diagnostic processes such as breast cancer and lung cancer diagnostics, by detecting the cancers in early stages. AI also reduces the instances of false positives in lung cancer screening, thus, improving lung cancer detection accuracy. For instance, researchers at the Naval Medical Center San Diego and Google's AI research division Google AI developed a reliable solution comprised of cancer-detecting algorithms used for autonomous evaluation of lymph node biopsies. This AI solution improved the accuracy of metastatic breast cancer detection to 99%. The cancer diagnostics market is regulated by the FDA which imposes restrictions on cancer diagnostic devices such as magnetic resonance imaging (MRI) and nuclear magnetic resonance spectroscopy (NMR). The FDA categorizes these devices into the Class II category, as they have a moderate risk associated with usage. Class II devices are bounded by device-specific regulations which include performance standards, premarket data requirements, post market surveillance, and labeling requirements associated with their usage. For instance, the labeling of such devices is required to have a list of contraindications, adverse reactions, precautions, warnings, and other instructions before being released in the market. Hence, regulations such as these would keep a check on manufacturers of cancer diagnostics devices. Major players in the cancer diagnostics market are Abbott, Becton Dickinson and Company, Hoffmann-La Roche Ltd., GE Healthcare Ltd., Thermo Fisher Scientific, Siemens Healthcare GmbH, Accuray, Illumina, Elekta AB, and C.R. BardInc. North America was the largest region in the cancer diagnostics market in 2022. Asia-Pacific was the second-largest region in the global cancer diagnostics market. The regions covered in the global cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The cancer diagnostics market consists of sales of pathology-based instruments (slide staining systems, tissue processing systems, cell processors, PCR instruments, NGS instruments, and other pathology-based instruments), imaging Instruments (CT systems, ultrasound systems, MRI systems, mammography systems, and nuclear imaging systems) and biopsy instruments that are used for the diagnosis of cancer. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global cancer diagnostics market is segmented - 1) By Products: Companion Diagnostics, Molecular Diagnostics 2) By End-User: Cancer Research Institutes, Diagnostic Laboratories, Hospitals, Other End Users 3) By Method: Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging 4) By Application: Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma, Other Applications

Breast cancer is characterised by uncontrolled growth of cells in the breast, causing lumps. The breast cancer diagnostic devices are used to diagnose cancer that occurs in the breasts. The main types of breast cancer diagnostics are imaging, biopsy, genomic tests, blood tests, and others. A biopsy is the process of removing a piece of tissue or a sample of cells from the body so that it can be tested in a laboratory. The technologies involved is fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), and other technologies. The cancer types involved are BRCA breast cancer, ER and PR breast cancer, her type 2-breast cancer, EGFR mutation test breast cancer, and others. The diagnostic types involved are ionising breast imaging technologies and non-ionizing imaging technologies. The end-users involved are hospitals and clinics, cancer research centers, diagnostic laboratories, and ambulatory surgical centers. The breast cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides breast cancer diagnostics market statistics, including breast cancer diagnostics industry global market size, regional shares, competitors with a breast cancer diagnostics market share, detailed breast cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer diagnostics industry. This breast cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global breast cancer diagnostics market grew from $4.06 billion in 2022 to $4.4 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The breast cancer diagnostics market is expected to grow from $5.86 billion in 2027 at a CAGR of 7.4%. The increasing incidence of breast cancer will require more equipment to diagnose, which will further increase the demand for the breast cancer diagnostics market. Breast cancer is the most common form of cancer, affecting 2.1 million women every year, and causing the largest number of deaths from cancer in women. The goal of the early diagnosis is to improve the percentage of breast cancers diagnosed at an initial point so that more successful care will be used and the risk of death from breast cancer can be reduced. According to the World Health Organization (WHO), around 2.3 million women were diagnosed with breast cancer and 685,000 people died of breast cancer in 2020. Therefore, the increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market. The high cost of diagnosis of breast cancer is a key factor that hinders the growth of the market for diagnostics of breast cancer. The cost of diagnosis for breast cancer typically rose with the initiation of the diagnostic stage of the disease. According to HealthMatch, in 2020, the total cost of breast cancer treatment ranged between $20,000 and $100,000. The diagnosis alone ranged between $151 and $751 in various regions. Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market. Technological advancement is a key trend in the breast cancer diagnostics market. Several new techniques have been developed which could be used in the diagnosis and treatment of breast cancer. The 3D mammography, also known as breast tomosynthesis, takes photographs around the breast from various angles and translates them into a 3-D model. In September 2022, Niramai, an Indian Health-Tech company, launched an innovative solution called Thermalytix. It is a automated breast cancer screening and diagnostic tool which combines thermal imaging and AI. In January 2021, Hologic, a US-based women’s health medtech company, acquired Somatex Medical for $64 million. The acquisition would support Hologic’s strategy to provide comprehensive solutions for breast health care. Somatex is a German-based provider of Breast cancer diagnostic services. Major players in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., and C.R. Bard Inc. North America was the largest region in the breast cancer diagnostics market in 2022. Asia-Pacific was the second largest region in the global breast cancer diagnostics market. The regions covered in the global breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the breast cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The breast cancer diagnostics market consists of sales of instruments such as analyzer, reagents and others that are used for the diagnosis of breast cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global breast cancer diagnostics market is segmented - 1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types 2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies 3) By Cancer Type: BRCA Breast Cancer, ER & PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types 4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies 5) By End Users: Hospitals and Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

Tumor ablation therapy devices are minimally invasive devices used in the treatment of tumors, commonly of kidney, liver and lung. The main technologies in the tumor ablation therapy devices are radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others. Irreversible electroporation (IRE) in tumor ablation therapy is a new tissue ablation method in which micro to millisecond electrical pulses are supplied to undesirable tissue to produce cell necrosis by irreversible cell membrane permeabilization. The treatments included are surgical, laparoscopic, and percutaneous that are used in various applications such as kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and others. The various end-users of tumor ablation therapy devices are hospitals, oncology clinics, and others. The tumor ablation therapy devices market research report is one of a series of new reports from The Business Research Company that provides tumor ablation therapy devices market statistics, including tumor ablation therapy devices industry global market size, regional shares, competitors with a tumor ablation therapy devices market share, detailed tumor ablation therapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor ablation therapy devices industry. This tumor ablation therapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global tumor ablation therapy devices market grew from $0.56 billion in 2022 to $0.64 billion in 2023 at a compound annual growth rate (CAGR) of 15.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The tumor ablation therapy devices market is expected to grow from $1.1 billion in 2027 at a CAGR of 14.4%. The increasing prevalence of cancer is a key factor driving the growth of the tumor ablation therapy devices market. Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. Tumor ablation is a minimally invasive procedure widely used in the treatment of lung, liver, kidney, and bone tumors. For instance, in 2020, according to the American Institute of cancer research, there were an estimated 18.1 million cancer cases around the world. It was estimated that 9.3 million cases were in men and 8.8 million in women. Among them, lung and breast cancers are the most common cancers in the world, and about 12.5% and 12.2% of the new cases are diagnosed in 2020. The procedure is an effective method for patients who have failed chemotherapy or radiotherapy, thereby supporting the growth of the tumor ablation therapy devices market. Product recalls of tumor ablation devices due to technical issues are expected to hinder the growth of the tumor ablation therapy devices market. The companies are retrieving their products from the market due to safety concerns. For instance, COVIDien Emprint Long Percutaneous Antenna with Thermosphere Technology, a tumor ablation device from Medtronic had recalled its devices due to the disengagement of ceramic trocar tip of the Emprint ablation from the needle shaft post-ablation. Similarly, in June 2018, Accurian RF Ablation by Medtronic Sofamor Danek USA Inc. was recalled due to the difficulty in insertion. The product recalls caused a financial burden on the companies hindering the tumor ablation therapy devices market. Major companies operating in the tumor ablation therapy devices are focusing on technology advancements for shorter procedures, increased safety, lower exposure to radiation, faster learning curves, and improved outcomes J&J medicals have released a microwave ablation system called NEUWAVE, which is the first minimally invasive device to put electrodes into cancer cells and thereby increase the temperature around them for burning the cancer cells. In June 2020, Boston Scientific has launched a technology called DirectSense technology, a tool used for monitoring the effect of radiofrequency (RF) now for cardiac procedures, which may be further employed for tumors. In August 2022, Imagin Medical, a Canada-based urologic oncology company acquired enCAGE Coil™ Precision Ablation System for Prostate Cancer from TROD Medical NV for $2.5m. The acquisition would strengthen Imagin’s position as a urologic oncology company and expand its portfolio in the field of prostate cancer. TROD Medical NV is a Belgium-based medical device company. Major players in the tumor ablation therapy devices market are Galil Medical Inc., Misonix Inc., HealthTronics, Angiodynamics, Boston Scientific Corporation, Medtronic PLC., EDAP TMS S.A, Neuwave Medical Inc., BVM Medical Limited, and Erbe Elektromedizin GmbH. North America was the largest region in the tumor ablation therapy devices market in 2022. Asia-Pacific was the second largest region in the global tumor ablation therapy devices market. The regions covered in the global tumor ablation therapy devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the tumor ablation therapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The tumor ablation therapy devices market consists of sales of radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others that are used for tumor ablation therapies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global tumor ablation therapy devices market is segmented - 1) By Technology: Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation, Other Technologies 2) By Treatment: Surgical, Laparoscopic, Percutaneous 3) By End User: Hospitals, Oncology Clinics, Other End Users 4) By Application: Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Other Applications

Community oncology includes a private physician who does not work for a hospitals or a medical institution. It is used for community welfare purposes. The main types of community oncology services are small community oncology clinics, medium community oncology clinics, and large community oncology clinics. A small oncology clinic is comprised of a single oncologist, with one office and a support staff of physician extenders, nurses, pharmacists, or pharmacy technicians and other staff. The different types of cancers include breast cancer, lung cancer, kidney cancer, liver cancer, ovarian cancer, prostate cancer, skin cancer, pancreatic cancer, blood cancer, colorectal cancer, others and involve various therapies such as medical oncology, radiation oncology, surgical oncology, others. The community oncology services market research report is one of a series of new reports from The Business Research Company that provides community oncology services market statistics, including community oncology services industry global market size, regional shares, competitors with a community oncology services market share, detailed community oncology services market segments, market trends and opportunities, and any further data you may need to thrive in the community oncology services industry. This community oncology services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global community oncology services market size will grow from $47.95 billion in 2022 to $53.79 billion in 2023 at a compound annual growth rate (CAGR) of 12.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global community oncology services market size is expected to grow to $81.33 billion in 2027 at a CAGR of 10.9%. The lower-cost care in community oncology centres is anticipated to boost the demand for the community oncology service market. The cancer care services are considered to be cost-effective in community oncology centres as compared to hospitals. According to the Community Oncology Alliance’s report published, the cost of cancer care per patient per month for various tumors in community-based clinics (CCs) was approximately $12,000 whereas the cost of cancer care in hospital-based oncology clinics (HCs) was about $20,000. Furthermore, the cost per patient per month for treatment of chemotherapy in a community setting was nearly $5,000 compared to around $8,500 in hospital-based clinics. Hence, the low cost of community oncology settings or community oncology centres is expected to drive the demand for the community oncology services market over the forecast years. Coronavirus outbreak is likely to act as a major restraint for the growth of the community oncology services market during the forecast period. The World Health Organization (WHO) declared the COVID-19 outbreak as pandemic on March 11, 2020. Coronavirus has created a significant risk of mortality for cancer patients worldwide. COVID-19 is predicted to have a long-term impact on oncology practices. According to a survey conducted by the Medical Group Management Association in April 2020, the healthcare practices recorded a decline of 55% in the revenue and a 60% decline in the patient volume since the beginning of the COVID-19 pandemic. Moreover, according to a survey of 51 USA oncologists conducted by MJH Life Sciences during May 2020, 73% of the oncologist limited their surgeries to urgent cases, 53% modified dosing regimens to reduce in-patient visits, and 71% had canceled routine office visits of the patients. Therefore, the coronavirus outbreak has caused a rapid decline in overall oncology in-person services, subsequently impacting the community oncology services market. Major companies are undergoing various acquisitions and research collaborations in the community oncology services market to expand their services and offerings, which is gaining significant popularity over recent years. According to a report published by Community Oncology Alliance in April 2020, the rate of community oncology practices acquired by hospitals increased by 9.7% between 2018 and 2020. For instance, in August 2020, The Community Cancer Centre, a US-based clinic engaged in providing community-based cancer care, was acquired by Carle Health. Carle Health is a US-based hospital and healthcare company with more than 9,500 employees in its five hospitals and associated healthcare business. In October 2021, Anova Enterprises, Inc., a US-based healthcare technology company partnered with OPN Healthcare. Through this partnership, Anova will fund the growing OPN Healthcare research program and all practices in the OPN network will continue to employ the AnovaOSTM technology platform to speed up patient access to experimental medicines. OPN Healthcare is a US-based community oncology company. Major players in the community oncology services market are Community Care Physicians P.C., Nebraska Cancer Specialists, US Oncology, Inc. (McKesson Corporation), Tufts Medical Centre., Doctors Medical Centre, Oncology Specialists, S.C. and Baptist Cancer Centre. North America was the largest region in the oncology services market in 2022. Western Europe was the second largest region in the global oncology services market. The regions covered in the global community oncology services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the community oncology services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The community oncology services market includes revenues earned by entities by providing diagnostic, corrective and preventive treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global community oncology services market is segmented - 1) By Type: Small Community Oncology Clinics, Medium Community Oncology Clinics, Large Community Oncology Clinics 2) By Cancer Type: Breast Cancer, Lung Cancer, Kidney Cancer, Liver Cancer, Ovarian Cancer, Prostate Cancer, Skin Cancer, Pancreatic Cancer, Blood Cancer, Colorectal Cancer, Other Cancers 3) By Therapy Type: Medical Oncology, Radiation Oncology, Surgical Oncology, Other Therapies